Dr Reddy's Q4 results 2026: Profit plunges 86% YoY to ₹220 crore; board recommends a final dividend of ₹8 ...

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower ...

The court also asked Dr. Reddy’s to file a fresh undertaking detailing the status of compliance since the March 30 order, ...

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dr. Reddy’s Laboratories Ltd. on Wednesday announced the launch of Lenalidomide Capsules in the United States market. According to the company, this is the therapeutic equivalent generic version of ...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in ...

Dr Reddy’s Laboratories, which maintained its lead over Aurobindo till FY25, fell behind it in FY26 with a total revenue of ...

Company launches Obeda after introducing generic semaglutide injections in India and Canada; oral diabetes therapy cleared ...

An FDA warning letter to Dr. Reddy's Laboratories ($RDY) shows that inspectors found many of the data manipulation issues and contamination concerns that have landed ...

Good day, everyone and welcome to the Quarter 4 and Full Year FY '26 Earnings Call of Dr. Reddy's Laboratories Limited. I'm Aishwarya Sitharam, Head of Investor Relations of Dr. Reddy's. Joining us ...

SINGAPORE--(BUSINESS WIRE)--Prestige BioPharma Ltd. (KRX: 950210) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) ...